Dare Bioscience, Inc. (NASDAQ:DARE) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET
Company Participants
Sabrina Martucci Johnson - President and Chief Executive Officer
John Fair - Chief Strategy Officer
Lisa Walters-Hoffert - Chief Financial Officer
Conference Call Participants
Zegbah Jallah - ROTH Capital Partners
Douglas Tsao - H.C. Wainwright
Kumaraguru Raja - Brookline Capital Markets
Operator
Welcome to the conference call hosted by Dare Bioscience to review the company's financial results for the year ended March 31, 2022, and to provide a general business update. This call is being recorded. My name is Delfin, and I'll be your operator today.
With us today are Ms. Sabrina Martucci Johnson, Dare's President and Chief Executive Officer; Mr. John Fair, Dare's Chief Strategy Officer; and Ms. Lisa Walters-Hoffert, Dare's Chief Financial Officer.
Ms. Johnson, please proceed.
Sabrina Martucci Johnson
Thank you. Good afternoon, and welcome to our First Quarter 2022 Financial Results and Business Update Call for Dare Bioscience. Our plan today is to review our first quarter results, discuss developments since our last call in March, and use the time to view our business strategy and highlight our objectives and milestones anticipated for 2022.
Before we begin, I'd like to remind you that today's discussion will include forward-looking statements within the meaning of Federal Securities Laws which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements.
Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties, you should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our annual report on Form 10-K for the year ended December 31st, 2021, which is filed on March 31, 2022.
I would also like to point out that the content of this call includes time-sensitive information that is current only as of today, May 12, 2022. Dare undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law.
As you know, Dare is solely and squarely focused in women's health. It is our belief that prioritizing women's health is not only good for the many women lacking effective or convenient therapeutic choices, but also for a broad set of stakeholders, including their families, partners, and of course, our shareholders.